Dr. Sreelatha Chalasani, MD

Dr. Chalasani practices at The Carolina Center for Rheumatology and Arthritis Care, PA in Rock Hill, South Carolina.

Dr. Chalasani's NPI, 1063618080, was assigned on June 26, 2007. Dr. Chalasani holds South Carolina license MD52058.

Dr. Chalasani's primary practice is The Carolina Center for Rheumatology and Arthritis Care, PA, at 744 Arden Ln, Rock Hill, SC 29732 in York County. The practice phone is (803) 329-1660.

Dr. Chalasani's primary practice is The Carolina Center for Rheumatology and Arthritis Care, PA in Rock Hill, South Carolina. Dr. Chalasani is also affiliated with Rock Hill Hospital - Piedmont Medical Network. The medical group on file is The Carolina Center for Rheumatology and Arthritis Care. Dmand AI also links Dr. Chalasani to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chalasani practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Chalasani's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Chalasani's licenses on file in 2 states: South Carolina and Wisconsin.

CMS data shows 127,691 Medicare services from Dr. Chalasani across 21 procedure codes in 2024, for 607 Medicare patients. Medicare paid $1,658,795 for them. Every service was in an office.

CMS counts 607 Medicare patients who saw Dr. Chalasani in 2024. The largest group is 75 to 84, with 262 patients. 75% of them have arthritis, and 75% have high blood pressure. Their average risk score is 1.24, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chalasani's median patient age at 71, with 84% women.

In 2024, Dr. Chalasani wrote 2,510 Medicare Part D claims for 471 patients. 91% of them were for generic drugs. CMS names the drug for 2,428 of them, across 21 drugs with 11 or more claims each, at $481,534 in total drug cost. In 2023, CMS named 2,640 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Chalasani for performance year 2024, reported as part of a group. Dr. Chalasani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Chalasani, published from 2010 to 2013. Dr. Chalasani has published most often in Clin Med Res. Dr. Chalasani's most frequent co-authors are Vijay Hotchand Aswani, MD, Shankar S. Bettadahalli, MD and William G. Hocking, MD.

CMS Open Payments shows 622 general payments to Dr. Chalasani from 41 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Amgen Inc. paid the most, $2,707.